INSM INSMED Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INSM

Price (delayed)

$26.17

Market cap

$3.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.27

Enterprise value

$4.49B

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved ...

Highlights
The company's gross profit rose by 26% YoY and by 6% QoQ
INSM's revenue is up by 22% year-on-year and by 4.7% since the previous quarter
INSMED's net income has shrunk by 67% YoY and by 27% QoQ
The debt has soared by 61% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.insmed.com
Peers: SRPT GILD ALIM ARRY

Key stats

What are the main financial stats of INSM
Market
Shares outstanding
143.8M
Market cap
$3.76B
Enterprise value
$4.49B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
13.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.66
Earnings
Revenue
$269.47M
EBIT
-$633.91M
EBITDA
-$613.76M
Free cash flow
-$475.63M
Per share
EPS
-$5.27
Free cash flow per share
-$3.46
Book value per share
-$1.14
Revenue per share
$1.96
TBVPS
$8.99
Balance sheet
Total assets
$1.44B
Total liabilities
$1.59B
Debt
$1.34B
Equity
-$155.75M
Working capital
$848.17M
Liquidity
Debt to equity
-8.6
Current ratio
5.15
Quick ratio
4.64
Net debt/EBITDA
-1.18
Margins
EBITDA margin
-227.8%
Gross margin
78.9%
Net margin
-258.2%
Operating margin
-246%
Efficiency
Return on assets
-49.6%
Return on equity
N/A
Return on invested capital
-43.5%
Return on capital employed
-51.3%
Return on sales
-235.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INSM stock price

How has the INSMED stock price performed over time
Intraday
-0.65%
1 week
-1.65%
1 month
20.88%
1 year
18.04%
YTD
30.98%
QTD
24.03%

Financial performance

How have INSMED's revenue and profit performed over time
Revenue
$269.47M
Gross profit
$212.51M
Operating income
-$662.86M
Net income
-$695.84M
Gross margin
78.9%
Net margin
-258.2%
INSMED's operating income has shrunk by 74% YoY and by 29% QoQ
INSMED's net income has shrunk by 67% YoY and by 27% QoQ
INSMED's operating margin has decreased by 43% YoY and by 23% from the previous quarter
The net margin has contracted by 37% YoY and by 22% from the previous quarter

Growth

What is INSMED's growth rate over time

Valuation

What is INSMED stock price valuation
P/E
N/A
P/B
N/A
P/S
13.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.66
The EPS has dropped by 50% year-on-year and by 23% since the previous quarter
INSM's price to sales (P/S) is 43% lower than its 5-year quarterly average of 23.3 but 32% higher than its last 4 quarters average of 10.1
INSM's revenue is up by 22% year-on-year and by 4.7% since the previous quarter

Efficiency

How efficient is INSMED business performance
The company's return on assets fell by 42% YoY and by 18% QoQ
The ROS has declined by 34% year-on-year and by 21% since the previous quarter
The ROIC has declined by 13% since the previous quarter and by 7% year-on-year

Dividends

What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INSM.

Financial health

How did INSMED financials performed over time
INSM's total assets is 10% lower than its total liabilities
INSMED's total liabilities has soared by 58% YoY and by 2.1% from the previous quarter
INSM's total assets is up by 37% YoY but it is down by 5% QoQ
The debt to equity has plunged by 146% YoY but it has soared by 71% from the previous quarter
The debt has soared by 61% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.